542 followers
⑥LUME-meso試験 P2/3 未治療 CDDP+PEM±オフェブ 主要評価項目のPFSは6.8vs7.0か月と延長は期待できないって話 https://t.co/CmUUvqu8IB
⑥LUME-meso試験 P2/3 未治療 CDDP+PEM±オフェブ 主要評価項目のPFSは6.8vs7.0か月と延長は期待できないって話 https://t.co/CmUUvqu8IB
RT @DrFbarron: Nintedanib could be a new option of treatment in patients with mesothelioma. Results From the LUME-Meso Trial. https://t.co/…
New2Trip: Nintedanib Plus Pemetrexed/Cisplatin in Patients w/ Malignant Pleural Mesothelioma: Phase II Results From … https://t.co/O7m1M8hxB1
New2Trip: Nintedanib Plus Pemetrexed/Cisplatin in Patients w/ Malignant Pleural Mesothelioma: Phase II Results From … https://t.co/O7m1M8hxB1